Use of omalizumab to improve desensitization safety in allergen immunotherapy

Désirée Larenas-Linnemann*, Ulrich Wahn, Matthias Kopp

*Corresponding author for this work
Original languageEnglish
JournalJournal of Allergy and Clinical Immunology
Volume133
Issue number3
Pages (from-to)937-937.e2
Number of pages3
ISSN0091-6749
DOIs
Publication statusPublished - 03.2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research Areas and Centers

  • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

Cite this